---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-037073"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:40:51.599023+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PDS Biotechnology enters $50M ATM equity offering program with B. Riley and H.C. Wainwright

## Summary
- New at-the-market sales agreement allows up to $50M in common stock through B. Riley Securities and H.C. Wainwright.
- Replaces prior August 2022 ATM program; 3% commission on gross proceeds to agents.
- Shares sold via Rule 415 at-the-market on Nasdaq Capital Market; no minimum sales obligation.
- Prior ATM agreement with B. Riley and BTIG terminated effective August 13, 2024.
- Proceeds from any future sales will be used for general corporate purposes.

## SEC filing metadata
- accession: 0001140361-24-037073
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124037073/0001140361-24-037073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124037073/ny20034050x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-037073
- JSON: https://secwatch.observer/filing/0001140361-24-037073.json
- Plain text: https://secwatch.observer/filing/0001140361-24-037073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.